South China Morning Post · drug outlicensing deals

China biotech deals hit record as innovative drugs draw interest of multinationals

· By Daniel Ren
Story summary

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements

Read at South China Morning Post

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.